A 6-month open-label extension study of the long-term safety of DVS SR [desvenlafaxine succinate sustained-release] in outpatients with fibromyalgia syndrome
Phase of Trial: Phase II/III
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Desvenlafaxine (Primary)
- Indications Fibromyalgia
- Focus Adverse reactions
- Sponsors Wyeth
- 15 Mar 2017 Status changed from completed to discontinued according to results published in the Clinical Pharmacology in Drug Development.
- 05 Dec 2007 Status change from in progress to completed.
- 14 Feb 2007 New trial record.